律师事务所对UroGen Pharma提起集体诉讼,指控UroGen Pharma未能披露药物试验问题。 Law firms file class action lawsuits against UroGen Pharma over alleged failures in disclosing drug trial issues.

Robbins LLP和Pomerantz律师事务所代表2023年7月至2025年5月购买UroGen Pharma股票的投资者提出集体诉讼。 Robbins LLP and Pomerantz Law Firm are filing class action lawsuits on behalf of investors who bought UroGen Pharma's stocks between July 2023 and May 2025. 这些诉讼声称,UroGen没有披露其牵头药物UGN-102临床试验的问题,该药物缺乏适当的控制小组。 The lawsuits allege that UroGen failed to disclose issues with its lead drug UGN-102's clinical trial, which lacked a proper control group. 美国食品和药物管理局质疑试验数据的充分性,导致UroGen的股价下跌. The FDA questioned the adequacy of the trial data, leading to a decline in UroGen's stock price. 这些诉讼寻求为受影响的投资者追回损失。 The lawsuits seek to recover losses for the investors affected.